Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557384 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04557384 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 3 participants.
The verdict
NCT04557384, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.
Interventions
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2021-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557384
The ClinicalTrials.gov registry entry for NCT04557384 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ramucirumab is the first listed.
NCT04557384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04557384 about?
NCT04557384 is a clinical study titled "A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer". The purpose of this study in participants with advanced cancer is to learn more about the safety of ramucirumab when given by injection under the skin (subcutaneous injection). The study will also measure how much ramucirumab gets into the bloodstream and how long it takes the body to get rid of it.
What is the current status of trial NCT04557384?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-02-23. Estimated completion is 2021-05-25.
What interventions are being tested in trial NCT04557384?
The interventions under investigation include: Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT04557384?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.